Psychosis with sibutramine [12]

Journal of Clinical Psychopharmacology

Volumn 27, Issue 3, 2007, Pages 315-317

  Rosenbohm, Angela ^a   Bux, Christoph J ^a   Connemann, Bernhard J ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; SERTINDOLE; SIBUTRAMINE; ANOREXIGENIC AGENT; CYCLOBUTANE DERIVATIVE;

ADULT; AGGRESSION; AGITATION; ANXIETY; APATHY; ATTENTION DISTURBANCE; AUDITORY HALLUCINATION; BODY MASS; CASE REPORT; DEPRESSION; DRUG WITHDRAWAL; FEMALE; HUMAN; JEALOUS DELUSION; LETTER; MALE; PERSECUTORY DELUSION; PRIORITY JOURNAL; PSYCHOSIS; VISUAL HALLUCINATION; WEIGHT REDUCTION; MIDDLE AGED; OBESITY;

ADULT; APPETITE DEPRESSANTS; CYCLOBUTANES; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 34248529812     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000270083.38124.1f     Document Type: Letter

References (15)

1. Luque CA, Rey JA. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother. 1999;33:968-978.
2. Berkowitz RI, Fujioka K, Daniels SR, et al. Sibutramine Adolescent Study Group. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med. 2006;145:81-90.
3. Taflinski T, Chojnacka J. Sibutramine-associated psychotic episode. Am J Psychiatry. 2000;157:2057-2058.
4. Heal DJ, Aspley S, Prow MR, et al. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from D-amphetamine and D-fenfluramine. Int J Obes Relat Metab Disord. 1998;22(suppl 1)S18-S28.
5. Xu J, Chen JD. Peripheral mechanisms of sibutramine involving proximal gastric motility in dogs. Obesity (Silver Spring). 2006;14:1363-1370.
6. Henderson DC, Copeland PM, Borba CP, et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry. 2005;162:954-962.
7. Reznik I, Sirota P. An open study of fluvoxamine augmentation of neuroleptics in schizophrenia with obsessive and compulsive symptoms. Clin Neuropharmacol. 2000;23:157-160.
8. Goff DC, Brotman AW, Waites M, et al. Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry. 1990;147:492-494.
9. Neumann M, Livak V, Paul HW, et al. Acute psychosis after administration of bupropion hydrochloride (Zyban). Pharmacopsychiatry. 2002;35:247-248.
10. Golden RN, James SP, Sherer MA, et al. Psychoses associated with bupropion treatment. Am J Psychiatry. 1985;142:1459-1462.
11. Howard WT, Warnock JK. Bupropion-induced psychosis. Am J Psychiatry. 1999;156:2017-2018.
12. Haid RW, Gutmann L, Crosby TW. Wernicke-Korsakoff encephalopathy after gastric placation. JAMA. 1982;247:2566-2567.
13. Abarbanel JM, Berginer VM, Osimani A, et al. Neurologic complications after gastric restriction surgery for morbid obesity. Neurology. 1987;37:196-200.
14. Cirignotta F, Manconi M, Mondini S, et al. Wernicke-Korsakoff encephalopathy and polyneuropathy after gastroplasty for morbid obesity. Arch Neurol. 2000;57:1356-1359.
15. Robinson S, Winnik HZ. Severe psychotic disturbances following crash diet weight loss. Arch Gen Psychiatry. 1973;29:559-562.